CDK4 and nut midline carcinoma: For instance, combining CDK4/6 inhibitors or EZH2 inhibitors with BET inhibitors has demonstrated synergy, and currently, new phase I combination trials are being tested in NUT carcinoma in the USA (NCT05372640, NCT05019716, NCT05488548).